Clinical trials: Relapsed Leukemia
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
This study evaluates ADCT-301 in participants with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). Participants will participate in a dose-escalation phase (Part 1) and receive ADCT-301 either weekly or once…
- Trial name
- NCT02588092
- Testing
- ADCT-301
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- ADC Therapeutics S.A.
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r…
- Trial name
- ZUMA-8 (NCT03624036)
- Testing
- brexucabtagene autoleucel, Fludarabine, Cyclophosphamide
- Where
- 22 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Acute Lymphoblastic Leukemia
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in…
- Trial name
- NCT05687032
- Testing
- inotuzumab ozogamicin
- Where
- 16 sites in China
- Volunteers
- 44 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication ( FLT3-ITD) positive.
- Trial name
- NCT01565668
- Testing
- AC220
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 76 people
- Sponsor
- Daiichi Sankyo
Chronic Lymphocytic Leukemia
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) patients with DDR deficiencies.
- Trial name
- CORONADO CLL (NCT05405309)
- Testing
- RP-3500, Olaparib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
The relapse of acute leukemia, MDS and blast phase CML after allogeneic transplantation affects approximately 1/3 to 1/2 of all transplant recipients and is the main cause of treatment failure.
- Trial name
- NCT00548847
- Testing
- GM-CSF, Interferon-α-2b
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Leukemia
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total-body irradiation (TBI) before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00416884
- Testing
- Campath, Fludarabine, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a Phase 1, multicenter, open-label study to evaluate safety, tolerability and pharmacokinetics of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT03671564
- Testing
- Milademetan
- Where
- 8 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Leukemia
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Giving intensity modulated radiation therapy (IMRT) and chemotherapy, such as etoposide and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00576979
- Testing
- cyclophosphamide, etoposide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, Plasma Cell Leukemia
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are…
- Trial name
- NCT00615589
- Testing
- Fludarabine/Busulfan x 4 days, stem cell transplant
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
This phase II trial studies the side effects lirilumab and azacitidine and to see how well they work in treating patients with acute myeloid leukemia that has not responded to treatment or has returned after a period of…
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02399917
- Testing
- Azacitidine, Lirilumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL)
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Background: Most patients with acute lymphoblastic leukemia (ALL) and many patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and non-Hodgkin's lymphoma (NHL) have a protein called Wilm's Tumor 1…
- Conditions
- Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT00923910
- Testing
- WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma
- Trial name
- NCT01885897
- Testing
- ALT-803
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma.
- Conditions
- Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma
- Trial name
- NCT02370160
- Testing
- DT2219ARL
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00119392
- Testing
- rituximab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myelogenous Leukemia
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
The goal of this clinical study is to find out whether continued therapy with decitabine after achieving a remission in acute myeloid leukemia (AML) patients can help prolong the remission and prevent relapse of the disease.
- Trial name
- NCT00398983
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Nivolumab in AML in Remission at High Risk for Relapse
This phase II trial studies how well nivolumab works in treating patients with acute myeloid leukemia that has decreased or disappeared but may still be in the body (remission), and is at high risk for returning (relapse).
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Blasts Under 10 Percent of Bone Marrow Nucleated Cells, Therapy-Related Myeloid Neoplasm
- Trial name
- NCT02532231
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).
- Trial name
- NCT00355472
- Testing
- KW-0761
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.